Selected Recent Reviews and Primary Research Articles

Hillis AL, Toker A. Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer. Cancer Cell. 2020 Oct 12;38(4):441-443. doi: 10.1016/j.ccell.2020.09.011. PMID: 33049205.

Liu H, Paddock MN, Wang H, Murphy CJ, Geck RC, Navarro AJ, Wulf GM, Elemento O, Haucke V, Cantley LC, Toker A. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. Cancer Discov. 2020 Aug;10(8):1226-1239. doi: 10.1158/2159-8290.CD-19-1262. Epub 2020 Jun 8. PMID: 32513774; PMCID: PMC7415683.

Geck RC, Foley JR, Murray Stewart T, Asara JM, Casero RA Jr, Toker A. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. J Biol Chem. 2020 May 8;295(19):6263-6277. doi: 10.1074/jbc.RA119.012376. Epub 2020 Mar 5. PMID: 32139506; PMCID: PMC7212655.

You I, Erickson EC, Donovan KA, Eleuteri NA, Fischer ES, Gray NS, Toker A. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem Biol. 2020 Jan 16;27(1):66-73.e7. doi: 10.1016/j.chembiol.2019.11.014. Epub 2019 Dec 16. PMID: 31859249; PMCID: PMC6980747.

Toker A. Double trouble for cancer gene. Science. 2019 Nov 8;366(6466):685-686. doi: 10.1126/science.aaz4016. PMID: 31699922.

Guo J, Dai X, Laurent B, Zheng N, Gan W, Zhang J, Guo A, Yuan M, Liu P, Asara JM, Toker A, Shi Y, Pandolfi PP, Wei W. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019 Feb;21(2):226-237. doi: 10.1038/s41556-018-0261-6. Epub 2019 Jan 28. PMID: 30692625; PMCID: PMC6377565.

Toker A, Dibble CC. PI 3-Kinase Signaling: AKTing up inside the Cell. Mol Cell. 2018 Sep 20;71(6):875-876. doi: 10.1016/j.molcel.2018.09.006. PMID: 30241602.

Clement E, Inuzuka H, Nihira NT, Wei W, Toker A. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Sci Signal. 2018 Mar 13;11(521):eaao3810. doi: 10.1126/scisignal.aao3810. PMID: 29535262; PMCID: PMC5902813.

Lien EC, Ghisolfi L, Geck RC, Asara JM, Toker A. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT. Sci Signal. 2017 Dec 19;10(510):eaao6604. doi: 10.1126/scisignal.aao6604. PMID: 29259101; PMCID: PMC5808948.

Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001. PMID: 28431241; PMCID: PMC5546324.

Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017 Apr;45:62-71. doi: 10.1016/ Epub 2017 Mar 24. PMID: 28343126; PMCID: PMC5482768.

Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of <i>De Novo</i> Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2. Erratum in: Cancer Discov. 2017 Jul;7(7):782. PMID: 28255083; PMCID: PMC5380483.

Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal. 2017 Feb 21;10(467):eaah4674. doi: 10.1126/scisignal.aah4674. PMID: 28223411; PMCID: PMC5858194.

Shimizu K, Fukushima H, Ogura K, Lien EC, Nihira NT, Zhang J, North BJ, Guo A, Nagashima K, Nakagawa T, Hoshikawa S, Watahiki A, Okabe K, Yamada A, Toker A, Asara JM, Fukumoto S, Nakayama KI, Nakayama K, Inuzuka H, Wei W. The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. 2017 Jan 3;10(460):eaah4117. doi: 10.1126/scisignal.aah4117. PMID: 28049764; PMCID: PMC5215841.

Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2017 Feb 1;77(3):790-801. doi: 10.1158/0008-5472.CAN-16-2400. Epub 2016 Dec 9. PMID: 27940576; PMCID: PMC5290090.

Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M, Novak J, Cheng JQ, Toker A, Signoretti S, Zhang Q, Asara JM, Kaelin WG Jr, Wei W. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 Aug 26;353(6302):929-32. doi: 10.1126/science.aad5755. PMID: 27563096; PMCID: PMC5326551.

Geck RC, Toker A. Nonessential amino acid metabolism in breast cancer. Adv Biol Regul. 2016 Sep;62:11-17. doi: 10.1016/j.jbior.2016.01.001. Epub 2016 Jan 21. PMID: 26838061.

Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov. 2015 Nov;5(11):1194-209. doi: 10.1158/2159-8290.CD-15-0460. Epub 2015 Aug 20. PMID: 26293922; PMCID:


Toker A, Rameh L. PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K? Cancer Cell. 2015 Aug 10;28(2):143-5. doi: 10.1016/j.ccell.2015.07.010. PMID: 26267528.

Brown KK, Montaser-Kouhsari L, Beck AH, Toker A. MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. Cell Rep. 2015 Jun 9;11(9):1358-66. doi: 10.1016/j.celrep.2015.05.004. Epub 2015 May 28. PMID: 26027929; PMCID: PMC4464897.

Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, Luo HR, Beck AH, Toker A. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol. 2015 Jun;9(6):1140-54. doi: 10.1016/j.molonc.2015.02.004. Epub 2015 Feb 19. PMID: 25735562; PMCID: PMC4439371.

Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell. 2014 Nov 20;56(4):595-607. doi: 10.1016/j.molcel.2014.09.023. Epub 2014 Oct 30. PMID: 25458846; PMCID: PMC4255362.

Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014 Aug;4(8):942-55. doi: 10.1158/2159-8290.CD-13-0873. Epub 2014 May 16. PMID: 24838891; PMCID: PMC4125464.

Toker A, Chin YR. Akt-ing up on SRPK1: oncogene or tumor suppressor? Mol Cell. 2014 May 8;54(3):329-30. doi: 10.1016/j.molcel.2014.04.020. PMID: 24813709; PMCID: PMC4089875.

Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul. 2014 May;55:28-38. doi: 10.1016/j.jbior.2014.04.001. Epub 2014 Apr 19. PMID: 24794538; PMCID:PMC4062840.

Elloul S, Kedrin D, Knoblauch NW, Beck AH, Toker A. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Mol Cancer Res. 2014 Mar;12(3):464-76. doi: 10.1158/1541-7786.MCR-13-0398. Epub 2013 Nov 22. PMID: 24269953; PMCID: PMC3962723.

Toker A. Phosphoinositide 3-kinases-a historical perspective. Subcell Biochem. 2012;58:95-110. doi: 10.1007/978-94-007-3012-0_4. PMID: 22403075.

Toker A. Achieving specificity in Akt signaling in cancer. Adv Biol Regul. 2012 Jan;52(1):78-87. doi: 10.1016/j.advenzreg.2011.09.020. PMID: 21986444; PMCID: PMC3614006.

Chin YR, Toker A. Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr. 2011 May- Jun;5(3):211-4. doi: 10.4161/cam.5.3.15790. Epub 2011 May 1. PMID: 21519185; PMCID: PMC3210203.

Chin YR, Toker A. Akt2 regulates expression of the actin-bundling protein palladin. FEBS Lett. 2010 Dec 1;584(23):4769-74. doi: 10.1016/j.febslet.2010.10.056. Epub 2010 Nov 2. PMID: 21050850; PMCID: PMC2997733.

Toker A. TTC3 ubiquitination terminates Akt-ivation. Dev Cell. 2009 Dec;17(6):752-4. doi: 10.1016/j.devcel.2009.12.003. PMID: 20059946.

Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 2009 Apr;21(4):470-6. doi: 10.1016/j.cellsig.2008.11.015. Epub 2008 Dec 7. PMID: 19110052; PMCID: PMC2719559.

Toker A. mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell. 2008 Jul 11;31(1):6-8. doi: 10.1016/j.molcel.2008.06.007. PMID: 18614042.

Toker A. Akt signaling: a damaging interaction makes good. Trends Biochem Sci. 2008 Aug;33(8):356-9. doi: 10.1016/j.tibs.2008.05.003. Epub 2008 Jun 26. PMID: 18585043.

Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006 Apr 15;66(8):3963-6. doi: 10.1158/0008-5472.CAN-06-0743. PMID: 16618711.

Toker A. The biology and biochemistry of diacylglycerol signalling. Meeting on molecular advances in diacylglycerol signalling. EMBO Rep. 2005 Apr;6(4):310-4. doi: 10.1038/sj.embor.7400378. PMID: 15791268; PMCID: PMC1299288.

Storz P, Döppler H, Ferran C, Grey ST, Toker A. Functional dichotomy of A20 in apoptotic and necrotic cell death. Biochem J. 2005 Apr 1;387(Pt 1):47-55.

doi: 10.1042/BJ20041443. PMID: 15527421; PMCID: PMC1134931.